A RandoMised study of best Available therapy versus JAK Inhibition in patients with high risk Polycythaemia Vera or Essential Thrombocythaemia who are resistant or intolerant to HydroxyCarbamide.
Phase of Trial: Phase II
Latest Information Update: 09 Aug 2017
At a glance
- Drugs Ruxolitinib (Primary)
- Indications Essential thrombocythaemia; Polycythaemia vera
- Focus Therapeutic Use
- Acronyms MAJIC
- 09 Aug 2017 Results (n=116) assessing safety and efficacy data for essential thrombocytopenia population, published in the Blood.
- 06 Dec 2016 Results (n=110) presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
- 03 Nov 2016 According to Incyte Corporation media release, data will be presented at 58th Annual American Society of Hematology (ASH) meeting 2016.